Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 18/20 | 1.00 |
| ▸ | CDK1 | P06493 | 17/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9920620 | 0.83 | MAPKAPK2 (0.71) | MAPKAPK2CDK1PRKD1 | |
| SCHEMBL6320514 | 0.82 | MAPKAPK2 (0.69) | MAPKAPK2CDK1PRKD1KDM4ENPC1 | |
| SCHEMBL15472007 | 0.81 | MAPKAPK2 (0.68) | MAPKAPK2CDK1PRKD1KDM4EALDH1A1 | |
| SCHEMBL6311137 | 0.81 | MAPKAPK2 (1.00) | MAPKAPK2CDK1 | |
| SCHEMBL6314208 | 0.81 | MAPKAPK2 (1.00) | MAPKAPK2CDK1 | |
| SCHEMBL6320092 | 0.81 | MAPKAPK2 (0.82) | MAPKAPK2CDK1PRKD1 | |
| SCHEMBL6310787 | 0.81 | MAPKAPK2 (0.82) | MAPKAPK2CDK1PRKD1 | |
| SCHEMBL6312607 | 0.81 | MAPKAPK2 (0.82) | MAPKAPK2CDK1PRKD1 | |
| SCHEMBL6311690 | 0.81 | MAPKAPK2 (1.00) | MAPKAPK2CDK1 | |
| SCHEMBL15504847 | 0.80 | MAPKAPK2 (0.80) | MAPKAPK2CDK1PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | claimed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | claimed |
| US-20050250765-A1 | Diazepinones as antiviral agents | CHO HIDETSURA | 2005-11-10 | — | — | US | disclosed |
| US-20040116410-A1 | Diazepinones as antiviral agents | CHO HIDETSURA (JP) | 2004-06-17 | — | — | US | disclosed |
| WO-2002014324-A2 | DIAZEPINONES AS ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250765-A1 | Diazepinones as antiviral agents | ZC3HAV1, ECI1, ZC3HAV1L | MAPKAPK2 3952/4885CDK1 274/4885PRKD1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.